Sun Pharma’s Phase 3 Clinical Studies Evaluating Tildrakizumab 100 mg (ILUMYA) in Active Psoriatic Arthritis Meet their Primary Endpoint
פוסטים אחרונים
- Sun Pharma signs Definitive Agreement to Acquire Organon
- Sun Pharma launches its semaglutide injection under the brand names, Noveltreat and Sematrinity in India
- Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis
- Sun Pharma Comes on Board as Principal Sponsor and Health Partner of Royal Challengers Bengaluru (RCB) for T20 Season 2026
- Sun Pharma reports Q3FY26 results
תגובות אחרונות